Benzoate Drugs for Traumatic Brain Injury

TL;DR

This review explores the potential of benzoate drugs, like sodium benzoate and glyceryl tribenzoate, as possible treatments for traumatic brain injury.

Contribution

The paper evaluates two FDA-approved benzoates as novel therapeutic candidates for traumatic brain injury.

Findings

Sodium benzoate and glyceryl tribenzoate show potential in reducing TBI-related pathologies in rodent studies.

These benzoates are already FDA-approved for other uses, suggesting a pathway for repurposing in TBI treatment.

The review highlights the need for further research into benzoates as therapeutic options for TBI.

Abstract

Traumatic brain injury (TBI) is an acute disorder with prolonged complexities that affirm to be the leading cause of deaths and disabilities in US. The pathophysiology of TBI comprises of multiple complex processes. An impactful insult results in tissue damage, neuroinflammation, impaired cerebral blood flow, BBB disruption, and demyelination, leading to neurodegeneration and functional impairments. There are no specific treatments for TBI. Recent studies highlight the potential efficacy of the following benzoates for attenuating TBI pathologies in rodents:
Sodium benzoate, a metabolite of cinnamon, a widely used food additive and a Food and Drug Administration (FDA)-approved drug for glycine encephalopathyGlyceryl tribenzoate, FDA-approved flavoring element being used in food and food packing productions
In this review, we have made a genuine attempt to evaluate the significance of these two benzoates as prospective therapeutic options for TBI.

Sodium benzoate, a metabolite of cinnamon, a widely used food additive and a Food and Drug Administration (FDA)-approved drug for glycine encephalopathy

Glyceryl tribenzoate, FDA-approved flavoring element being used in food and food packing productions

Figures